Pear Therapeutics, Inc. announced on 18 November it launched its prescription digital therapeutics dubbed Somryst aimed to help patients 22 and older with chronic insomnia.
The Somryst app was the first product to receive US Food and Drug Administration clearance in March under the agency’s software precertification pilot program. The app delivers cognitive behavioral therapy for insomnia (CBTi) to train the brain and body to sleep. The program is designed to take patients through short lessons and challenges over a six-to-nine-week period, based on an algorithm to restrict sleep to a schedule to improve sleep, while also providing clinicians with real-time data on the patient’s progress